Ayala Pharmaceuticalsincis A Clinical Stage Oncology Company Based In Monmouth Junctionnew Jerseyfounded In 1987The Company Specializes In Developing Precision Therapies For Rare Tumors And Aggressive Cancersayala Focuses On Small Molecule Therapeutics That Target Specific Genetic Alterationsparticularly In The Notch Signaling Pathway The Company S Key Products Include Al102An Oral Gamma Secretase Inhibitor For Desmoid Tumorsaspacytarabinebst 236 A Proprietary Anti Metabolite For Acute Myeloid Leukemiaamlin Patients Unfit For Intensive Chemotherapyand Bms 906024Another Gamma Secretase Inhibitor Repositioned For Precision Medicine Applicationsayala S Clinical Programs Emphasize A Precision Medicine Approachselecting Patients Based On Genetic Markers To Improve Treatment Outcomes Ayala Pharmaceuticals Is Committed To Addressing High Unmet Needs In Oncologyparticularly In Rare Cancer Indicationsthe Company Has Established Strategic Partnerships And Is Led By Experienced Industry Professionalspositioning Itself To Make Significant Contributions To The Field Of Oncology
